Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. (Q35622833)

9 August 2017

1 reference

title

Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. (English)

1 reference

9 August 2017

Alain H Rook

1

1 reference

9 August 2017

Timothy M Kuzel

series ordinal

2

1 reference

9 August 2017

Elise A Olsen

series ordinal

3

1 reference

9 August 2017

publication date

1 December 2003

1 reference

Hematology / Oncology Clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

17

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

1435-48, ix

1 reference

Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Aberrant Cytokine Production By Sezary Syndrome Patients: Cytokine Secretion Pattern Resembles Murine Th2 Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Alpha interferon in the treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Interferon alfa-2a in the treatment of cutaneous T cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Topical chemotherapy and immunotherapy of mycosis fungoides: intermediate-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Intralesional interferon in the treatment of early mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Interferons: effectiveness, toxicities, and costs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Actions of interferon alpha and interleukin- 1 beta on the glucose-responsive neurons in the ventromedial hypothalamus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Interferons in the treatment of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Treatment of Neurotoxic Side Effects of Interferon-α with Naltrexone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Role of extracorporeal photochemotherapy alone and in combination with interferon alfa in the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900109-6

7 January 2021

10.1016/S0889-8588(03)00109-6

Identifiers

DOI

1 reference

9 August 2017

1 reference